May 15, 2023Verve Therapeutics Announces Pipeline Progress and Expansion and Reports First Quarter 2023 Financial Results
May 09, 2023Verve Therapeutics to Participate in the RBC Capital Markets 2023 Global Healthcare Conference
Mar 27, 2023Verve Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day
Mar 03, 2023Verve Therapeutics Reports New Preclinical Data Demonstrating Potent and Durable Editing of ANGPTL3 Gene with VERVE-201 in Wild-type and LDLR-deficient Non-Human Primates
Mar 02, 2023Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
Feb 14, 2023Verve Therapeutics Announces VERVE-101 Awarded Innovation Passport by the UK MHRA for the Treatment of Heterozygous Familial Hypercholesterolemia
Nov 07, 2022Verve Therapeutics Provides Regulatory Update on VERVE-101 Investigational New Drug Application and Reports Third Quarter 2022 Financial Results
